Loading...

Biodesix, Inc.

BDSXNASDAQ
Healthcare
Medical - Diagnostics & Research
$0.45
$0.03(6.98%)

Biodesix, Inc. (BDSX) Financial Performance & Income Statement Overview

Explore the financials of Biodesix, Inc. (BDSX), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
45.30%
45.30%
Operating Income Growth
16.55%
16.55%
Net Income Growth
17.67%
17.67%
Operating Cash Flow Growth
-112.72%
112.72%
Operating Margin
-44.54%
44.54%
Gross Margin
78.77%
78.77%
Net Profit Margin
-53.66%
53.66%
ROE
-269.67%
269.67%
ROIC
-46.98%
46.98%

Biodesix, Inc. (BDSX) Income Statement & Financial Overview

Analyze Biodesix, Inc.’s BDSX earnings with segmented quarterly and yearly financial statement figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$17.96M$20.43M$18.15M$17.93M
Cost of Revenue$3.70M$4.34M$4.18M$3.88M
Gross Profit$14.26M$16.09M$13.97M$14.05M
Gross Profit Ratio$0.79$0.79$0.77$0.78
R&D Expenses$2.87M$2.41M$2.55M$2.56M
SG&A Expenses$20.45M$20.22M$20.02M$19.66M
Operating Expenses$23.39M$22.74M$22.56M$22.22M
Total Costs & Expenses$27.09M$27.08M$26.74M$26.09M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$1.69M$1.75M$2.04M$1.94M
Depreciation & Amortization$1.41M$1.40M$1.42M$1.32M
EBITDA-$8.01M-$5.10M-$6.80M-$7.55M
EBITDA Ratio-$0.45-$0.25-$0.37-$0.42
Operating Income-$9.14M-$6.65M-$8.59M-$8.17M
Operating Income Ratio-$0.51-$0.33-$0.47-$0.46
Other Income/Expenses (Net)-$1.97M-$1.60M-$1.67M-$2.57M
Income Before Tax-$11.10M-$8.25M-$10.26M-$10.81M
Income Before Tax Ratio-$0.62-$0.40-$0.57-$0.60
Income Tax Expense$0.00-$1.28M$0.00$0.00
Net Income-$11.10M-$8.25M-$10.26M-$10.81M
Net Income Ratio-$0.62-$0.40-$0.57-$0.60
EPS-$0.08-$0.06-$0.07-$0.09
Diluted EPS-$0.08-$0.06-$0.07-$0.09
Weighted Avg Shares Outstanding$146.55M$129.67M$146.30M$127.17M
Weighted Avg Shares Outstanding (Diluted)$146.55M$129.67M$146.30M$127.17M

Over the past four quarters, Biodesix, Inc. demonstrated steady revenue growth, increasing from $17.93M in Q2 2024 to $17.96M in Q1 2025. Operating income reached -$9.14M in Q1 2025, maintaining a consistent -51% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$8.01M, reflecting operational efficiency. Net income dropped to -$11.10M, with EPS at -$0.08. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;